Lv2
110 积分 2024-08-01 加入
Risk factors and clinical outcomes of extrahepatic recurrence in patients with post‐hepatectomy recurrent hepatocellular carcinoma
3个月前
已完结
Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma
4个月前
已完结
The Biological Meaning of Radiomic Features
5个月前
已完结
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
6个月前
已完结
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
6个月前
已完结
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
6个月前
已完结
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis
11个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
11个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
11个月前
已完结
Ena-bile-ing liver cancer growth
11个月前
已完结
皖公网安备34019202002308
